Manufacturer
DUOPHARMA MANUFACTURING (BANGI) SDN BHD
Contents
Betamethasone 17-valerate
Indication
Corticosteroid-responsive dermatoses.
Instruction
Apply thinly into affected area 1-3 times daily for up to 4 week or until improvement occurs
Drug interaction
Increased plasma concentration when used w/ CYP3A4 inhibitors (e.g. ritonavir, itraconazole), and OCs. Decreased therapeutic effect when concurrently used w/ rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone, aminoglutethimide and ephedrine. May antagonise the effect of hypoglycaemic agents, antihypertensives, neuromuscular blockers (e.g. vecuronium), and diuretics. Increased risk of hypokalaemia w/ acetazolamide, loop/thiazide diuretics, carbenoxolone, theophylline, cardiac glycosides. May inhibit the growth promoting effects of somatropin. Increased risk of tendon rupture w/ concurrent use of fluoroquinolones. May increase the metabolism of quetiapine and tretinoin. Increased risk of GI bleeding when used w/ NSAIDs. May enhance the efficacy of coumarin anticoagulants.
Malaysia
